HEARTMATE 3 LVAS IMPLANT KIT
Report
- Report Number
- 2916596-2020-03972
- Event Type
- Injury
- Date Received
- August 6, 2020
- Date of Event
- February 15, 2020
- Report Date
- September 18, 2020
- Manufacturer
- THORATEC CORPORATION
- Product Code
- DSQ
- UDI-DI
- 00813024013297
- PMA / PMN Number
- P160054
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- TX, US
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
Narratives
MANUFACTURER'S INVESTIGATION CONCLUSION: A DIRECT CORRELATION BETWEEN HEARTMATE 3 LVAS, SERIAL NUMBER (B)(6), AND THE REPORTED EVENTS (INFECTION, RENAL DYSFUNCTION, AND VOLUME OVERLOAD) COULD NOT CONCLUSIVELY BE DETERMINED THROUGH THIS INVESTIGATION. THE ACCOUNT COMMUNICATED THAT THE PATIENT EXPIRED ON (B)(6) 2020 (REFER TO CS-140263). THE PATIENT HAD PREVIOUSLY UNDERWENT A HEARTMATE II TO HEARTMATE 3 PUMP EXCHANGE ON (B)(6) 2019, AMID CONCERNS OF CHRONIC INFECTION (REFER TO CS-128070). PRIOR TO THE PATIENT¿S EXPIRATION, THE PATIENT WAS HOSPITALIZED OVER 15 TIMES DUE TO A CHRONIC DRIVELINE AND PUMP POCKET INFECTION. MOST OF THESE ADMISSIONS INCLUDED VOLUME OVERLOAD AND DIALYSIS RELATED ISSUES. THIS COMPLAINT ADDRESSES ADMISSION 8 OUT OF 15. NO FURTHER INFORMATION WAS PROVIDED BY THE ACCOUNT. THE HEARTMATE 3 LVAS IFU LISTS RENAL DYSFUNCTION AND INFECTION AS ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH THE USE OF HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM. CARE INSTRUCTIONS IN REGARD TO PREVENTING INFECTION ARE PROVIDED IN VARIOUS SECTIONS OF THE IFU. NO FURTHER INFORMATION WAS PROVIDED. THE MANUFACTURER IS CLOSING THE FILE ON THIS EVENT.
SECTION A2, H6 (PATIENT AND CONCLUSION CODES), AND H8: CORRECTION. CORRECTION - INTERNAL NUMBERS IN INVESTIGATION CONCLUSION REPLACED WITH MFR NUMBERS. MANUFACTURER'S INVESTIGATION CONCLUSION: A DIRECT CORRELATION BETWEEN HEARTMATE 3 LVAS, SERIAL NUMBER (B)(6), AND THE REPORTED EVENTS (INFECTION, RENAL DYSFUNCTION, AND VOLUME OVERLOAD) COULD NOT CONCLUSIVELY BE DETERMINED THROUGH THIS INVESTIGATION. THE ACCOUNT COMMUNICATED THAT THE PATIENT EXPIRED ON (B)(6) 2020, (REFER TO MFR#2916596-2020-03652). THE PATIENT HAD PREVIOUSLY UNDERWENT A HEARTMATE II TO HEARTMATE 3 PUMP EXCHANGE ON (B)(6) 2019, AMID CONCERNS OF CHRONIC INFECTION (REFER TO #MFR2916596-2019-03904). PRIOR TO THE PATIENT¿S EXPIRATION, THE PATIENT WAS HOSPITALIZED OVER 15 TIMES DUE TO A CHRONIC DRIVELINE AND PUMP POCKET INFECTION. MOST OF THESE ADMISSIONS INCLUDED VOLUME OVERLOAD AND DIALYSIS RELATED ISSUES. THIS COMPLAINT ADDRESSES ADMISSION 8 OUT OF 15. NO FURTHER INFORMATION WAS PROVIDED BY THE ACCOUNT. THE HEARTMATE 3 LVAS IFU LISTS RENAL DYSFUNCTION AND INFECTION AS ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH THE USE OF HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM. CARE INSTRUCTIONS IN REGARD TO PREVENTING INFECTION ARE PROVIDED IN VARIOUS SECTIONS OF THE IFU. NO FURTHER INFORMATION WAS PROVIDED. THE MANUFACTURER IS CLOSING THE FILE ON THIS EVENT.
EVENT DATE ESTIMATED AS ADMISSION DETAILS WERE NOT PROVIDED. DESCRIBE EVENT OR PROBLEM: THIS COMPLAINT WILL ADDRESS ADMISSION 8 OUT OF 15. THE EVENT IS BEING REPORTED CONSERVATIVELY. RELATED MANUFACTURER REPORT #'S: 2916596-2020-03961, 2916596-2020-03962, 2916596-2020-03963, 2916596-2020-03964, 2916596-2020-03969, 2916596-2020-03970, 2916596-2020-03971, 2916596-2020-03973, 2916596-2020-03975, 2916596-2020-03976, 2916596-2020-03977, 2916596-2020-03978, 2916596-2020-03979, 2916596-2020-03980. NO FURTHER INFORMATION WAS PROVIDED. A SUPPLEMENTAL REPORT WILL BE SUBMITTED WHEN THE MANUFACTURER¿S INVESTIGATION IS COMPLETED.
IT WAS REPORTED THAT THE PATIENT HAD OVER 15 ADMISSIONS WHERE CHRONIC DRIVELINE AND PUMP POCKET INFECTION WAS ADDRESSED. IT WAS ALSO NOTED THAT MOST OF THESE ADMISSIONS WERE FOR VOLUME OVERLOAD AND DIALYSIS RELATED NEEDS.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 840707 | HEARTMATE 3 LVAS IMPLANT KIT | VENTRICULAR (ASSISST) BYPASS | DSQ | THORATEC CORPORATION | 106524US | 7032579 | 00813024013297 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 58 YR | Hospitalization |